Last reviewed · How we verify
Clobex lotion
Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Psoriasis, Lichen planus.
At a glance
| Generic name | Clobex lotion |
|---|---|
| Also known as | clobetasol lotion, Clobex |
| Sponsor | Stiefel, a GSK Company |
| Drug class | Topical corticosteroid (Class I/Super-potent) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clobetasol propionate is a Class I (super-potent) corticosteroid that works by activating glucocorticoid receptors in skin cells, leading to decreased production of inflammatory mediators, reduced vasodilation, and suppression of immune cell infiltration. This results in rapid reduction of inflammation, itching, and other dermatological symptoms associated with various skin conditions.
Approved indications
- Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
- Psoriasis
- Lichen planus
- Atopic dermatitis
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Folliculitis
- Hypertrichosis
- Acneiform eruptions
- Hypopigmentation
Key clinical trials
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Silver Nitrate Versus Topical Steroid For Umbilical Granuloma (PHASE2)
- Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis (PHASE4)
- Intradermal LPS and Antibiotics (NA)
- Subject Preference for Scalp Psoriasis Treatment (PHASE3)
- Evaluation of the Vasoconstriction Properties of MC2-01 Cream (PHASE1)
- Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects (PHASE1)
- The Dose-response "Pilot" Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clobex lotion CI brief — competitive landscape report
- Clobex lotion updates RSS · CI watch RSS
- Stiefel, a GSK Company portfolio CI